BioNTech CEO Ugur Sahin (Photo by ddp images/Sipa USA)

BioN­Tech and Pfiz­er an­nounce $225M shin­gles vac­cine project, of­fer­ing mR­NA chal­lenger to Glax­o­SmithK­line's Shin­grix

One of the biggest sto­ry­lines of biotech’s next half-decade will be where Mod­er­na, BioN­Tech and their grow­ing list of ri­vals push the mR­NA tech­nol­o­gy that’s al­ready changed the world.

BioN­Tech and Pfiz­er gave part of the an­swer Wednes­day, an­nounc­ing a new part­ner­ship to co-de­vel­op an mR­NA-based shin­gles vac­cine. The can­di­date will be ready for ear­ly-stage tri­als in the sec­ond half of 2022, the com­pa­nies said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.